ストックスクリーナーアプリを入手
9.11
6.56%
-0.64
アフターアワーズ：
9.22
0.11
+1.21%
前日終値:
$9.75
開ける：
$9.98
24時間の取引高:
63,307
Relative Volume:
1.12
時価総額：
$178.74M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-15.57%
1か月 パフォーマンス:
-13.49%
6か月 パフォーマンス:
+3.88%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$9.08
$9.98
1週間の範囲:
$9.08
$11.99
52週間の値動き範囲:
$5.51
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
ACTU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
9.11 | 211.70M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Craig Hallum | Buy |
| 2025-03-17 | 開始されました | H.C. Wainwright | Buy |
Actuate Therapeutics Inc (ACTU) 最新ニュース
Actuate Therapeutics (NASDAQ:ACTU) Price Target Raised to $20.00 at HC Wainwright - Defense World
Actuate Therapeutics shares highlights from KOL eventon elraglusib data - Yahoo Finance
Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib - TipRanks
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - Barchart.com
Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - Yahoo Finance
Actuate Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - MENAFN.com
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - Insider Monkey
Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer (ACTU:NASDAQ) - Seeking Alpha
Actuate Therapeutics Presents Topline Elraglusib Phase 2 - GlobeNewswire
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire Inc.
P2P Group And NATO Registered Partner Aliter Showcases Inturai Stealthwave Video - The Globe and Mail
Actuate Therapeutics Elects Directors at Annual Meeting - TipRanks
Actuate Therapeutics Reports Phase 2 Trial Success Showing Improved Survival in Metastatic Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Details for 2025 ASCO Annual - GlobeNewswire
BIOS Capital Management LP Takes $78.75 Million Position in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Shares in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Apple Is Threatening to Challenge Alphabet's Empire: Is the Stock a Buy? - The Globe and Mail
Adding elraglusib seen to improve survival in pancreatic cancer trial - Rare Cancer News
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President - The Manila Times
Envestnet Asset Management Inc. Invests $83,000 in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Managing Adverse Events in Pembrolizumab Therapy for Gastric Cancer - Targeted Oncology
Actuate jumps as lead drug succeeds in mid-stage trial for pancreatic cancer - MSN
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech
Actuate Therapeutics to Host KOL Event on Topline Phase 2 - GlobeNewswire
Actuate Therapeutics to host KOL event on Phase 2 elraglusib data - TipRanks
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting - Yahoo Finance
PTC hits Huntington biomarker, but approval path still uncertain - biocentury.com
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data - Endpoints News
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Elraglusib shows survival benefit in pancreatic cancer trial - Investing.com Australia
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Elraglusib shows survival benefit in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Why Are Young Adults Getting More Pancreatic & Colon Cancer? - Targeted Oncology
Younger Adults See Sharp Rise in Pancreas & Colon Cancer, Study Shows - Targeted Oncology
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Actuate Therapeutics to Present Topline Phase 2 Data of Elraglusib at 2025 ASCO Annual Meeting - Nasdaq
Actuate to Present Elraglusib Phase 2 Topline Data at the - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum - Defense World
Craig-Hallum sets $21 target on Actuate Therapeutics stock By Investing.com - Investing.com Canada
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy Before Earnings Season Heats Up - The Globe and Mail
What Will Actuate Therapeutics Inc (NASDAQ: ACTU) Be Like In 2025 - stocksregister.com
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Actuate Therapeutics to Present Elraglusib Data for Advanced Salivary Gland Carcinoma at AACR Annual Meeting 2025 - Nasdaq
Actuate to Present Promising Data on Elraglusib in Advanced - GlobeNewswire
Actuate Therapeutics Inc (ACTU) 財務データ
Actuate Therapeutics Inc (ACTU) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):